logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10413547 B1

PDFFull Text
Date of Patent:
Sep. 17, 2019

Filed:

Sep. 26, 2018

Treatment of rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors

Applicant:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Inventors:

Jay Copeland Strum, Hillsborough, NC (US);

John E. Bisi, Apex, NC (US);

Patrick Joseph Roberts, Durham, NC (US);

Jessica A. Sorrentino, Durham, NC (US);

Assignee:

G1 Therapeutics, Inc., Research Park Triangle, NC (US);

Attorney:

Knowles Intellectual Property Strategies, LLC

Primary Examiner:

Yong L Chu

Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/5375 (2006.01); A61K 31/5377 (2006.01); A61K 31/695 (2006.01); A61K 31/4745 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/4745 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 31/695 (2013.01);
Abstract

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

Find Patent Forward Citations

Strum, Jay. (2019). Treatment of rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors (U.S. Patent No. 10413547). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10413547

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…